Atrasentan in Treating Patients With Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients
who have prostate cancer that has not responded to hormone therapy.